Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.